GE Announces General Manager for Bioprocess Business

GE Healthcare Life Sciences has appointed Emmanuel Ligner to the newly created role of General Manager overseeing worldwide commercial activities of its rapidly growing BioProcess business providing “start-to-finish” technologies and services for the biopharmaceutical and vaccine manufacturing industry.  Emmanuel reports to Nigel Darby, Vice President, BioProcess.

In March 2014 GE Healthcare Life Sciences expanded its offerings for the biopharmaceutical manufacturing industry through the acquisition of HyClone^TM cell culture sera and media.  This investment and other innovations such as KUBio^TM modular facility for the production of monoclonal antibodies are core to GE Healthcare’s strategy of helping the biopharmaceutical industry improve product yields and reduce time-to-market.

Before moving into this global role, Emmanuel was General Manager Commercial EMEA in January 2012, joining GE Healthcare in 2008 when the company acquired Whatman plc, a global supplier of filters and membranes for laboratory research, life sciences and medical diagnostic applications. Prior to Whatman, Emmanuel held a number of appointments in Japan with Abbott Diagnostics.